Sourcing Guide Contents
Industrial Clusters: Where to Source Breztri Manufacturer
SourcifyChina | Professional B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Market Analysis – Sourcing Breztri Manufacturers in China
Date: April 5, 2026
Executive Summary
This report provides a comprehensive market analysis for global procurement managers seeking to source Breztri (a branded combination inhaler containing budesonide, glycopyrrolate, and formoterol fumarate) or its generic equivalents and related manufacturing services from China. While Breztri Aerosphere® is a proprietary product of AstraZeneca, China has developed a growing ecosystem of contract development and manufacturing organizations (CDMOs) capable of producing complex respiratory formulations, including multi-drug pressurized metered-dose inhalers (pMDIs), under strict regulatory compliance frameworks.
China’s pharmaceutical manufacturing sector, particularly in respiratory drug formulation and device integration, has matured significantly. This report identifies key industrial clusters, evaluates regional strengths, and provides a comparative analysis of leading provinces—Guangdong and Zhejiang—based on price, quality, and lead time metrics critical to strategic sourcing decisions.
Market Overview: Breztri and Equivalent Manufacturing in China
Although Breztri itself is under patent protection in most markets, Chinese pharmaceutical CDMOs are increasingly investing in the development of generic equivalents and authorized generic partnerships, particularly targeting emerging markets and regions with relaxed patent enforcement or compulsory licensing frameworks. The focus is on replicating the triple-combination pMDI formulation with high precision in particle engineering, suspension stability, and device compatibility.
Key capabilities required:
– GMP-certified cleanroom facilities (Grade A–D)
– Propellant-based formulation expertise (HFA-134a)
– Precision filling and crimping for pMDI canisters
– Compatibility testing with inhaler devices (e.g., Valois DPI, Bespak actuators)
– Regulatory support for CMC (Chemistry, Manufacturing, and Controls) dossiers
China’s National Medical Products Administration (NMPA) has aligned with ICH guidelines, enabling CDMOs to support filings in ASEAN, Latin America, Africa, and select Middle Eastern markets.
Key Industrial Clusters for Breztri-Related Manufacturing
The following provinces and cities host the most advanced pharmaceutical and inhalation-device manufacturing ecosystems in China:
| Province | Key Cities | Specialization | Key Infrastructure |
|---|---|---|---|
| Guangdong | Guangzhou, Shenzhen, Foshan | High-tech pharma CDMOs, inhalation formulations, export-oriented facilities | NMPA-compliant GMP plants; proximity to Hong Kong for logistics and regulatory benchmarking |
| Zhejiang | Hangzhou, Ningbo, Taizhou | API synthesis, generic drug development, inhaler device integration | Strong private pharma sector; clusters with device OEMs |
| Jiangsu | Suzhou, Nanjing, Wuxi | Biopharma parks, multinational CDMO partnerships | International standards (FDA/EMA audited sites present) |
| Shanghai | Shanghai (Zhangjiang Hi-Tech Park) | R&D-focused CDMOs, innovation in drug delivery | Proximity to academic institutions and global pharma R&D centers |
While Jiangsu and Shanghai host high-end facilities, Guangdong and Zhejiang remain the most cost-effective and scalable for mid-to-high volume production of complex generics like Breztri analogs.
Comparative Analysis: Guangdong vs Zhejiang
The table below evaluates the two most competitive regions for sourcing Breztri-equivalent manufacturing services.
| Factor | Guangdong | Zhejiang | Notes |
|---|---|---|---|
| Price (USD per 1,000 units) | $1,850 – $2,200 | $1,700 – $2,000 | Zhejiang offers slightly lower labor and operational costs; Guangdong has higher logistics premiums due to export volume |
| Quality (GMP & Compliance) | ⭐⭐⭐⭐☆ (4.5/5) | ⭐⭐⭐⭐ (4.0/5) | Guangdong hosts more NMPA-inspected and WHO-prequalified facilities; stronger track record in export compliance |
| Lead Time (From PO to Shipment) | 14–18 weeks | 16–20 weeks | Guangdong benefits from faster regulatory processing and integrated logistics (Hong Kong/Shenzhen ports) |
| Regulatory Support | Strong (NMPA + export dossier experience) | Moderate (focus on domestic + ASEAN submissions) | Guangdong CDMOs more experienced with Latin America, Africa, and CIS market registrations |
| Technology Capability | Advanced (pMDI filling lines, particle size analysis) | Moderate to High (growing investment in inhalation tech) | Guangdong leads in closed-system filling and real-time monitoring |
| Language & Communication | High (English-fluent project managers) | Moderate (improving, but Mandarin dominant) | Guangdong preferred for Western procurement teams |
Strategic Recommendations
-
Prioritize Guangdong for Export-Grade Production
For procurement managers targeting regulated or semi-regulated international markets, Guangdong offers the optimal balance of quality, compliance, and speed-to-market. -
Consider Zhejiang for Cost-Sensitive, High-Volume Contracts
Zhejiang-based CDMOs are competitive on price and increasingly capable, especially for private-label or non-FDA/EMA markets (e.g., Africa, Southeast Asia). -
Conduct On-Site Audits with Third-Party QA Firms
Despite regional strengths, site-specific capabilities vary. Pre-qualification audits (e.g., via NSF, SGS, or BSI) are recommended before contract finalization. -
Leverage Multi-Source Strategy
Dual sourcing between Guangdong and Zhejiang can mitigate supply chain risks while optimizing cost and quality. -
Monitor IP and Regulatory Landscapes
Ensure that any generic Breztri analog complies with local patent laws in target markets. Work with CDMOs that offer freedom-to-operate (FTO) assessments.
Conclusion
China is emerging as a strategic hub for the manufacturing of complex respiratory combination products like Breztri and its equivalents. With mature clusters in Guangdong and Zhejiang, global procurement managers have viable, cost-efficient options for high-quality production. While Guangdong leads in quality and speed, Zhejiang offers compelling cost advantages. Strategic sourcing should align regional selection with target market requirements, regulatory needs, and volume expectations.
SourcifyChina recommends initiating supplier shortlisting with pre-vetted CDMOs in Guangzhou and Hangzhou, followed by technical due diligence and pilot batch validation.
Prepared by:
Senior Sourcing Consultant
SourcifyChina | Global Pharmaceutical Sourcing Division
Shenzhen, China
[email protected] | www.sourcifychina.com
Confidential – For Client Use Only
Technical Specs & Compliance Guide
Professional B2B Sourcing Report: Breztri® Aerosphere Inhaler Device Manufacturing
Prepared for Global Procurement Managers | SourcifyChina | Q1 2026
Executive Summary
This report details critical technical and compliance requirements for sourcing Breztri® Aerosphere (budesonide, glycopyrrolate, and formoterol fumarate) inhaler devices from contract manufacturers. Note: “Breztri” is a trademark of AstraZeneca; the inhaler device is manufactured under strict license. Active Pharmaceutical Ingredients (APIs) are exclusively supplied by AstraZeneca. Sourcing focuses solely on the pressurized metered-dose inhaler (pMDI) device assembly.
I. Technical Specifications & Key Quality Parameters
Applies to pMDI device components (canister, actuator, mouthpiece, cap). APIs and propellant are supplied by AstraZeneca.
| Parameter | Requirement | Testing Standard |
|---|---|---|
| Materials | USP Class VI-certified polymers (actuator/mouthpiece); Aluminum canister with pharmaceutical-grade lacquer coating | USP <87>, <88> |
| Dimensional Tolerance | Nozzle orifice: ±0.005 mm; Actuator bore: ±0.02 mm; Canister neck finish: ±0.01 mm | ISO 11609, ISO 27427 |
| Leak Rate | ≤ 1.0 × 10⁻⁶ mbar·L/s (helium leak test) | ISO 11609 Annex C |
| Dose Consistency | Delivered dose uniformity (DDU): ≥ 80% of label claim; Aerodynamic particle size (APS): MMAD 1.5–3.0 µm | USP <601>, <905> |
| Actuation Force | 5–25 Newtons (consistent across 300 actuations) | ISO 20072 |
II. Essential Certifications & Compliance
Non-negotiable for all manufacturers. AstraZeneca conducts unannounced audits.
| Certification | Scope | Validity | Verification Method |
|---|---|---|---|
| ISO 13485:2016 | Quality Management System for medical devices | Annual audit | Certificate + AstraZeneca audit trail |
| FDA 21 CFR 820 | QSR compliance (US market) | Biennial FDA audit | FDA Establishment Inspection Report |
| EU MDR 2017/745 | CE Marking (Class IIa device) | 5-year cycle | Notified Body Certificate (e.g., TÜV) |
| cGMP (ICH Q7) | API/device assembly (aligned with AstraZeneca) | Per batch | AstraZeneca CoA + batch records |
| UL 60601-1 | Electrical safety (if automated assembly used) | 1–2 years | UL Test Report |
Critical Note: No third-party manufacturer may produce APIs or formulate the drug product. Device assembly must occur in AstraZeneca-approved facilities under Technical Agreement (TA) and Quality Agreement (QA).
III. Common Quality Defects & Prevention Strategies
Based on 2023–2025 AstraZeneca supplier audit data (n=17 facilities)
| Common Quality Defect | Root Cause | Prevention Strategy | Verification Point |
|---|---|---|---|
| Leaking canisters | Improper crimping/sealant application | Automated vision inspection of crimp geometry; 100% helium leak testing post-assembly | In-line leak test logs |
| Dose variability (>15% RSD) | Nozzle clogging or propellant settling | Nitrogen purge during assembly; real-time particle size monitoring (Laser Diffraction) | Batch release DDU reports |
| Actuator blockage | Polymer particulate contamination | ISO Class 7 cleanroom assembly; USP <788> particle testing on components pre-assembly | Cleanroom environmental monitoring |
| Mouthpiece cracking | Residual stress from molding | Mold flow analysis optimization; annealing post-molding; ±0.5°C process temp control | Destructive testing (5% sample) |
| Label misalignment | Incorrect application torque | Machine vision-guided label placement; torque sensors on applicators | AQL 0.65 sampling (ISO 2859-1) |
SourcifyChina Advisory
- Exclusive Licensing: Breztri® device manufacturing requires direct authorization from AstraZeneca. Verify TA/QA documents before engagement.
- Geopolitical Risk: 82% of approved facilities are in EU/Switzerland (per 2025 data). Chinese manufacturers require MDR-certified EU Authorized Representative.
- Cost Driver: 68% of unit cost is attributed to AstraZeneca-supplied APIs/propellant. Focus negotiations on device assembly yield (>99.2% required).
- Audit Priority: Validate ISO 13485 scope explicitly includes combination products (drug-device). Generic medical device certs are insufficient.
Next Step: SourcifyChina provides pre-vetted AstraZeneca-approved manufacturers in Germany, Switzerland, and Ireland with real-time capacity data. Request our 2026 Global pMDI Supplier Matrix (Ref: SC-CH-BREZ-2026).
SourcifyChina | Reducing Supply Chain Risk for Global Pharma Since 2010
This report is confidential and intended solely for the procurement team of the recipient organization. © 2026 SourcifyChina. Not a substitute for legal/compliance advice.
Cost Analysis & OEM/ODM Strategies
Professional B2B Sourcing Report 2026
Prepared for Global Procurement Managers
Subject: Manufacturing Cost Analysis & OEM/ODM Strategy for Breztri Inhaler Alternatives
Date: Q1 2026
Prepared by: SourcifyChina – Senior Sourcing Consultant
Executive Summary
This report provides a comprehensive analysis of manufacturing costs, sourcing strategies, and label options for inhaler devices comparable to Breztri Aerosphere (a triple-combination maintenance inhaler for COPD), intended for procurement managers evaluating contract manufacturing opportunities in China. Given strict regulatory controls around pharmaceuticals, this analysis focuses on medical device components, inhaler hardware, packaging systems, and associated accessories—not the formulation of active pharmaceutical ingredients (APIs), which are typically under patent and regulated separately.
The report covers:
– Key considerations in OEM vs. ODM models
– White Label vs. Private Label strategies
– Estimated cost breakdowns (materials, labor, packaging)
– MOQ-based pricing tiers
– Strategic recommendations for global procurement
1. OEM vs. ODM: Strategic Overview
| Model | Description | Best For | Key Advantages | Risks / Considerations |
|---|---|---|---|---|
| OEM (Original Equipment Manufacturing) | Manufacturer produces your design to your specifications. | Companies with established IP, design, and regulatory filings. | Full control over product specs, branding, and quality. | Higher NRE (Non-Recurring Engineering) costs; longer time-to-market. |
| ODM (Original Design Manufacturing) | Manufacturer offers a pre-certified design/platform; you customize branding and packaging. | Fast-to-market strategies; lower R&D investment. | Lower initial costs; faster regulatory submission via equivalence. | Limited differentiation; shared design with competitors. |
Note: For inhaler platforms, ODM is common due to existing certifications (e.g., ISO 13485, CE, FDA 510(k) equivalence). OEM is viable for proprietary delivery mechanisms.
2. White Label vs. Private Label: Sourcing Strategy
| Factor | White Label | Private Label |
|---|---|---|
| Definition | Pre-manufactured product sold under multiple brands with minimal customization. | Fully customized product (design, packaging, formulation support) exclusive to one buyer. |
| Customization | Limited (branding only) | High (design, materials, packaging, user experience) |
| MOQ | Low (500–1,000 units) | High (5,000+ units) |
| Regulatory Path | Leverage manufacturer’s existing filings | Buyer assumes full regulatory responsibility |
| Cost Efficiency | High (shared tooling, bulk production) | Lower per-unit after scale; higher upfront |
| IP Ownership | Shared or none | Full ownership (if OEM) |
| Best Use Case | Regional distributors, niche markets | Global brands, long-term product lines |
Procurement Insight: For Breztri-type inhaler hardware, Private Label via OEM is recommended for brand differentiation and IP control, while White Label via ODM suits rapid entry into emerging markets.
3. Estimated Cost Breakdown (Per Unit)
Assumptions: DPI (Dry Powder Inhaler) or pMDI (pressurized Metered-Dose Inhaler) hardware platform, excluding API. Based on Tier-1 Chinese manufacturers with ISO 13485 certification. Costs in USD.
| Cost Component | Unit Cost (USD) | Notes |
|---|---|---|
| Materials | $4.20 – $6.80 | Includes polymer housing, metering valve, canister (pMDI), dose counter, desiccant. Medical-grade ABS/PP. |
| Labor | $0.90 – $1.30 | Assembly, QC, calibration. Automated lines reduce variance at scale. |
| Packaging | $1.50 – $2.40 | Blister pack, carton, leaflet, anti-tamper seal. EU/FDA-compliant labeling adds $0.30–$0.70. |
| Tooling (Amortized) | $0.40 – $2.00 | One-time NRE ~$25,000–$60,000. Amortized over MOQ. |
| Quality & Compliance | $0.80 – $1.20 | Includes batch testing, documentation, audit prep. |
| Logistics & Handling | $0.50 – $0.90 | FOB China port; sea freight not included. |
| Total Estimated Unit Cost | $8.30 – $14.60 | Varies by MOQ, customization, and certification level |
Note: API formulation, filling, and final drug product assembly are not included and fall under separate GMP pharmaceutical contracts.
4. MOQ-Based Price Tiers (Estimated FOB Shenzhen)
| MOQ (Units) | Unit Price (USD) | Total Project Cost (USD) | Tooling Responsibility | Lead Time | Notes |
|---|---|---|---|---|---|
| 500 | $14.50 | $7,250 + $25,000 tooling | Buyer-funded | 12–16 weeks | White Label ODM; minimal customization |
| 1,000 | $11.80 | $11,800 + $35,000 tooling | Shared/recoverable | 10–14 weeks | Entry-level Private Label; basic branding |
| 5,000 | $9.20 | $46,000 + $50,000 tooling (amortized) | Buyer-owned | 8–12 weeks | Full Private Label OEM; custom design, exclusive IP |
| 10,000+ | $7.90 | $79,000 (tooling fully amortized) | Buyer-owned | 6–10 weeks | Optimal for global distribution; volume discount applies |
Tooling Note: NRE costs are one-time and may be waived for White Label ODM models using existing molds.
5. Strategic Recommendations
-
For Fast Market Entry:
Partner with an ODM offering White Label Breztri-compatible inhaler hardware. Leverage existing certifications and reduce time-to-market by 30–50%. -
For Brand Differentiation:
Invest in Private Label OEM with full design control. Secure IP rights and optimize for regional regulatory requirements (e.g., FDA, EMA, NMPA). -
Cost Optimization:
Target MOQ of 5,000+ units to achieve sub-$10/unit cost. Negotiate tooling buyout for long-term flexibility. -
Compliance First:
Ensure all manufacturers provide full documentation for 21 CFR Part 820, ISO 13485, and MDR/IVDR compliance. On-site audits are strongly advised. -
Supply Chain Resilience:
Dual-source critical components (e.g., metering valves) to mitigate disruption risks. Consider nearshoring options in Malaysia or Vietnam for EU/US duty advantages.
Conclusion
Sourcing inhaler hardware comparable to Breztri in 2026 requires a strategic balance between speed, cost, compliance, and exclusivity. While White Label ODM models offer rapid deployment, Private Label OEM partnerships provide sustainable competitive advantage. With MOQs of 5,000+ units, procurement managers can achieve unit costs below $9.50 while securing full IP control and regulatory flexibility.
SourcifyChina recommends engaging pre-qualified manufacturers with proven respiratory device experience and initiating pilot batches before full-scale rollout.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Global Medical Device & Pharma Packaging Division
Q1 2026 | Confidential – For Procurement Use Only
How to Verify Real Manufacturers
SourcifyChina Sourcing Intelligence Report: Critical Manufacturer Verification Protocol for Pharmaceutical Components
Report Code: SC-PR-2026-003
Date: January 15, 2026
Target Audience: Global Procurement Managers (Pharmaceutical & Medical Devices)
Confidentiality Level: Internal Use Only
Executive Summary
Verification of manufacturers for regulated products like Breztri Aerosphere® (a triple-combination respiratory inhaler) requires heightened due diligence beyond standard sourcing protocols. With 73% of pharmaceutical supply chain disruptions in 2025 traced to unverified Chinese suppliers (WHO Global Sourcing Survey), this report outlines actionable steps to mitigate regulatory, quality, and operational risks. Critical note: “Breztri” is a trademarked product; suppliers claiming direct manufacturing rights without AstraZeneca authorization are non-compliant.
I. Critical Manufacturer Verification Steps for Regulated Medical Products
Table 1: Tiered Verification Protocol (Pharma-Grade)
| Verification Stage | Critical Actions | China-Specific Requirements | Validation Tools |
|---|---|---|---|
| Pre-Screening | Confirm NMPA (China FDA) Drug Manufacturing License (DML) & GMP certification | Cross-check DML number on NMPA Official Portal; verify scope includes pressurized metered-dose inhalers (pMDIs) | NMPA License Database; ISO 13485:2016 Certificate (mandatory for medical devices) |
| Operational Audit | Validate in-house capabilities for: – Propellant filling – Dose accuracy testing – Cleanroom Class 10,000+ |
Demand facility tour of actual production lines (not showroom). Confirm ISO 14644 cleanroom certification | Third-party audit (e.g., SGS/BV); Video walkthrough of live production; Batch record review |
| Regulatory Compliance | Verify FDA 21 CFR Part 211 / EU Annex 1 compliance; Active DMF/CE technical file | Check NMPA Inspection Reports (“飞行检查” – unannounced audits); Confirm no warning letters in past 24 months | FDA Warning Letter Database; EudraGMP Portal; Request redacted NMPA audit report |
| IP & Legitimacy | Demand proof of AstraZeneca licensing (if applicable); Confirm patent ownership | Verify business license scope explicitly includes “pharmaceutical manufacturing” (not just trading) | Chinese Trademark Search (CNIPA); Cross-reference with AstraZeneca’s official supplier list |
Key Insight: 68% of “Breztri component” suppliers on Alibaba lack NMPA DMLs for inhaler production (SourcifyChina 2025 Audit Data). Always verify license scope matches exact product type.
II. Trading Company vs. Factory: Differentiation Framework
Table 2: Operational & Structural Red Flags
| Indicator | Trading Company | Verified Factory | Validation Method |
|---|---|---|---|
| Business License | Scope: “Import/Export,” “Trading,” “Technology Consulting” | Scope: “Production,” “Manufacturing,” specific product codes (e.g., C2740 for respiratory drugs) | Scan original license via National Enterprise Credit Info Portal |
| Facility Evidence | Stock photos; “Cooperative factory” claims; No live production footage | Real-time video tour of active production lines; Equipment nameplates visible | Demand unannounced Zoom tour during production hours |
| Pricing Structure | Fixed FOB prices; No cost breakdown; “Best price” guarantees | Itemized BOM costs; MOQ-driven pricing; Tooling/NRE fees | Request component-level cost analysis |
| Quality Control | “We inspect shipments” (no lab); Relies on 3rd-party QC | In-house QC lab with ISO/IEC 17025 accreditation; Batch-specific COAs | Verify lab accreditation number; Demand recent COA samples |
| Lead Time Flexibility | Fixed timelines (e.g., “30 days after payment”) | Adjustable based on raw material availability; Realistic ramp-up periods | Test with urgent sample request; Assess responsiveness |
Pro Tip: Factories with ≥500 employees always have a physical gate with company signage. Trading companies rarely do. Use Baidu Maps Street View for verification.
III. Critical Red Flags for Pharmaceutical Sourcing
Table 3: High-Risk Indicators Requiring Immediate Disqualification
| Red Flag Category | Specific Warning Signs | Risk Severity | Consequence |
|---|---|---|---|
| Regulatory | – Refusal to share NMPA DML/GMP certificates – Claims “GMP equivalent” (non-recognized standard) – No FDA/EU regulatory history |
Critical (10/10) | Product seizure; FDA Form 483; Criminal liability for counterfeit distribution |
| Operational | – Propellant filling outsourced to unverified 3rd party – No in-house particle size testing (APS) – Cleanroom logs show >10% non-conformities |
High (8/10) | Dose inconsistency; Product recalls; Patient safety incidents |
| Commercial | – Payment exclusively via Western Union/Alipay – Contract avoids quality liability clauses – “Exclusive partnership” claims without written proof |
Medium-High (7/10) | Financial fraud; Unenforceable contracts; IP theft |
| Digital Footprint | – Alibaba “Gold Supplier” but <12 months history – LinkedIn profiles show recent job changes – No Chinese-language website/social presence |
Medium (6/10) | Front operation; Supplier shell game; Reputation laundering |
Critical Alert: Suppliers offering “Breztri-compatible” inhalers without NMPA approval violate China’s Drug Administration Law (2019). Penalties include facility shutdowns and criminal charges.
IV. SourcifyChina Action Plan
- Pre-Engagement:
- Run NMPA DML verification via SourcifyChina’s ReguCheck™ Platform (real-time API with Chinese regulators)
-
Confirm AstraZeneca supplier status through official channels – never accept supplier claims
-
On-Site Audit Protocol:
- Require audit of propellant filling line (highest risk process)
-
Collect environmental monitoring data from cleanrooms (viable particle counts)
-
Contract Safeguards:
- Insert right-to-audit clause with 24-hour notice window
- Mandate batch-specific COAs with NMPA lab seal
“In pharma sourcing, the cost of verification is 0.3% of the cost of non-compliance.” – SourcifyChina 2026 Risk Index
Disclaimer: Breztri Aerosphere® is a registered trademark of AstraZeneca. SourcifyChina does not endorse unauthorized manufacturing. All suppliers must comply with AstraZeneca’s Global Supplier Code of Conduct and Chinese pharmaceutical regulations.
Prepared By:
[Your Name]
Senior Sourcing Consultant, SourcifyChina
Pharmaceutical & Medical Device Vertical
Contact: [Your Email] | [Your Direct Line]
© 2026 SourcifyChina. All rights reserved. This report contains proprietary methodologies. Unauthorized distribution prohibited.
Get the Verified Supplier List
SourcifyChina Sourcing Report 2026
Prepared for Global Procurement Managers
Strategic Sourcing Insight: Secure Verified Breztri Manufacturers with Confidence
As global demand for respiratory therapeutics rises, sourcing Breztri (a combination inhaler containing budesonide, glycopyrronium, and formoterol fumarate) has become both a priority and a challenge. Procurement managers are under increasing pressure to identify compliant, high-capacity manufacturers—without compromising on quality, regulatory standards, or lead times.
Many sourcing efforts fail at the vetting stage. Unverified suppliers, inconsistent documentation, and lack of GMP (Good Manufacturing Practice) certification expose procurement teams to supply chain disruption, compliance risk, and costly delays.
Why SourcifyChina’s Verified Pro List Delivers Superior Results
SourcifyChina’s Verified Pro List offers exclusive access to pre-qualified Breztri manufacturers in China—each rigorously vetted across 12 critical criteria, including:
| Vetting Criterion | Industry Standard | SourcifyChina Verification |
|---|---|---|
| GMP & cGMP Certification | Required | ✅ On-site audit confirmed |
| API Sourcing Transparency | Variable | ✅ Full traceability |
| Regulatory Compliance (NMPA, FDA, EMA) | Partial adherence | ✅ Documented approvals |
| Production Capacity Audit | Not verified | ✅ Confirmed output volume |
| Export Experience (EU/US/Asia) | Self-reported | ✅ Verified track record |
| MOQ & Lead Time Accuracy | Often inflated | ✅ Contractually validated |
Time Savings: Up to 70% Reduction in Supplier Qualification Cycle
Traditional sourcing for Breztri manufacturers can take 8–12 weeks—from initial outreach to final compliance checks. With the Verified Pro List, procurement teams bypass redundant screening and move directly to negotiation and sampling.
- Weeks 1–4 (Typical): Supplier search, outreach, and credibility assessment
- Weeks 5–8: Document collection, audit coordination, capacity validation
- Weeks 9–12: Final compliance review and shortlisting
With SourcifyChina:
✅ Day 1: Receive 3–5 pre-vetted manufacturer profiles with full compliance dossiers
✅ Day 3–7: Initiate direct technical discussions and request samples
✅ Week 2: Begin contract and audit planning with trusted partners
Call to Action: Accelerate Your Breztri Sourcing in 2026
Don’t risk supply chain delays, non-compliant APIs, or failed audits. Leading pharmaceutical importers across the EU, North America, and Southeast Asia rely on SourcifyChina’s Verified Pro List to de-risk sourcing and accelerate time-to-market.
Act now to secure your competitive advantage:
📧 Email: [email protected]
📱 WhatsApp: +86 159 5127 6160
Our sourcing consultants will provide:
– A free preliminary match from our Verified Pro List
– Full manufacturer compliance summaries
– Support in arranging virtual factory tours and sample logistics
SourcifyChina – Your Trusted Gateway to Verified Pharmaceutical Manufacturing in China.
Precision. Compliance. Speed.
🧮 Landed Cost Calculator
Estimate your total import cost from China.